Our findings suggest that the blood levels of GFAP and YKL-40 reflect AD-related pathology, making both biomarkers strong candidates for inclusion in AD biomarker profiles characterizing a patient's neuropathophysiological state. Here, GFAP is linked to Alzheimer disease.